The first quarter of the year always tends to see a flurry Series A funding announcements. With so much attention focused on what you’ll say in your launch press release, what programs you’ll disclose on the website, and how you’ll explain your science to a broader audience for the first time, it can be hard to focus on anything beyond your exciting launch day. But what happens after a company publicly launches? Especially for early-stage biotechs, it may be quite a long time before there’s another significant milestone to announce. In the interim, how do you maintain momentum from your launch and stay on the radar of the audiences you want to reach? Enter social media. @ChrisJRailey shared his thoughts on the importance of social media and the role it plays in an early-stage biotech’s communications strategy. Check it out: bit.ly/47QDv6L

We had the privilege of working with so many amazing #TBCPartners over the course of 2023, none of which would be possible without our team of lifelong learners and passionate storytellers. We are eager to see what 2024 will bring in the world of biotech after we give our team time to reset and recharge between Christmas and New Year. From all of us at TBC, wishing everyone a happy and healthy holiday season.